These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 32850726)

  • 1. Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System.
    Xu R; Shi M; Li J; Song P; Li N
    Front Bioeng Biotechnol; 2020; 8():862. PubMed ID: 32850726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudotyping Improves the Yield of Functional SARS-CoV-2 Virus-like Particles (VLPs) as Tools for Vaccine and Therapeutic Development.
    Zak AJ; Hoang T; Yee CM; Rizvi SM; Prabhu P; Wen F
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian cells-based platforms for the generation of SARS-CoV-2 virus-like particles.
    Elfayres G; Paswan RR; Sika L; Girard MP; Khalfi S; Letanneur C; Milette K; Singh A; Kobinger G; Berthoux L
    J Virol Methods; 2023 Dec; 322():114835. PubMed ID: 37871706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Efficient and Scalable Method for the Production of Immunogenic SARS-CoV-2 Virus-like Particles (VLP) from a Mammalian Suspension Cell Line.
    Hirschberg S; Ghazaani F; Ben Amor G; Pydde M; Nagel A; Germani S; Monica L; Schlör A; Bauer H; Hornung J; Voetz M; Dwai Y; Scheer B; Ringel F; Kamal-Eddin O; Harms C; Füner J; Adrian L; Pruß A; Schulze-Forster K; Hanack K; Kamhieh-Milz J
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal system for assembly of SARS-CoV-2 virus like particles.
    Swann H; Sharma A; Preece B; Peterson A; Eldredge C; Belnap DM; Vershinin M; Saffarian S
    Sci Rep; 2020 Dec; 10(1):21877. PubMed ID: 33318562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Fluorescence-Tagged SARS-CoV-2 Virus-like Particles by a Tri-Cistronic Vector Expression System for Investigating the Cellular Entry of SARS-CoV-2.
    Chang YS; Chu LW; Chen ZY; Wu JS; Su WC; Yang CJ; Ping YH; Lin CW
    Viruses; 2022 Dec; 14(12):. PubMed ID: 36560829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: A systematic review of virus-like particles of coronavirus: Assembly, generation, chimerism and their application in basic research and in the clinic.
    Lu W; Zhao Z; Huang YW; Wang B
    Int J Biol Macromol; 2022 Mar; 200():487-497. PubMed ID: 35065135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells.
    Alpuche-Lazcano SP; Stuible M; Akache B; Tran A; Kelly J; Hrapovic S; Robotham A; Haqqani A; Star A; Renner TM; Blouin J; Maltais JS; Cass B; Cui K; Cho JY; Wang X; Zoubchenok D; Dudani R; Duque D; McCluskie MJ; Durocher Y
    Commun Med (Lond); 2023 Aug; 3(1):116. PubMed ID: 37612423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized production and fluorescent labeling of SARS-CoV-2 virus-like particles.
    Gourdelier M; Swain J; Arone C; Mouttou A; Bracquemond D; Merida P; Saffarian S; Lyonnais S; Favard C; Muriaux D
    Sci Rep; 2022 Aug; 12(1):14651. PubMed ID: 36030323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid and Scalable Production of Functional SARS-CoV-2 Virus-like Particles (VLPs) by a Stable HEK293 Cell Pool.
    Puarattana-Aroonkorn S; Tharakaraman K; Suriyawipada D; Ruchirawat M; Fuangthong M; Sasisekharan R; Artpradit C
    Vaccines (Basel); 2024 May; 12(6):. PubMed ID: 38932290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
    Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of virus-like particles with inbuilt immunostimulatory properties as vaccine candidates.
    Collett S; Earnest L; Carrera Montoya J; Edeling MA; Yap A; Wong CY; Christiansen D; Roberts J; Mumford J; Lecouturier V; Pavot V; Marco S; Loi JK; Simmons C; Gulab SA; Mackenzie JM; Elbourne A; Ramsland PA; Cameron G; Hans D; Godfrey DI; Torresi J
    Front Microbiol; 2023; 14():1065609. PubMed ID: 37350788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and discrimination of spike protein in SARS-CoV-2 virus-like particles via surface-enhanced Raman spectroscopy.
    Akdeniz M; Al-Shaebi Z; Altunbek M; Bayraktar C; Kayabolen A; Bagci-Onder T; Aydin O
    Biotechnol J; 2024 Jan; 19(1):e2300191. PubMed ID: 37750467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV envelope protein palmitoylation or nucleocapid association is not required for promoting virus-like particle production.
    Tseng YT; Wang SM; Huang KJ; Wang CT
    J Biomed Sci; 2014 Apr; 21(1):34. PubMed ID: 24766657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells.
    Kumar CS; Singh B; Rizvi ZA; Parray HA; Verma JK; Ghosh S; Mukhopadhyay A; Awasthi A; Shrivastava T; Banerjee M
    ACS Infect Dis; 2022 Oct; 8(10):2119-2132. PubMed ID: 36129193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system.
    Mortola E; Roy P
    FEBS Lett; 2004 Oct; 576(1-2):174-8. PubMed ID: 15474033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2.
    Boix-Besora A; Lorenzo E; Lavado-García J; Gòdia F; Cervera L
    Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Virus-like Particles with Plasmonic Au Cores and S1-Spike Protein Coronas.
    Andrzejewska W; Peplińska B; Litowczenko J; Obstarczyk P; Olesiak-Bańska J; Jurga S; Lewandowski M
    ACS Synth Biol; 2023 Aug; 12(8):2320-2328. PubMed ID: 37449651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Strengths of Scanning Electron Microscopy in Deciphering SARS-CoV-2 Infectious Cycle.
    Brahim Belhaouari D; Fontanini A; Baudoin JP; Haddad G; Le Bideau M; Bou Khalil JY; Raoult D; La Scola B
    Front Microbiol; 2020; 11():2014. PubMed ID: 32973730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.